Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Outline: This is a multi-center study.
Chemotherapy/radiation therapy (2 cycles)
- Cisplatin 50 mg/m2 IV days 1 and 8 of 28 day cycle
- Etoposide 50 mg/m2 IV days 1-5 of 28 day cycle
- Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy) with the following:
Maintenance therapy of Sorafenib 400 mg PO BID of 28 day cycle, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 1 year.
Patients with progressive disease will discontinue treatment.
ECOG performance status 0 or 1
Hematopoietic:
- Absolute neutrophil count (ANC) ≥ 1500 mm3
- Platelet count ≥ 100,000 mm3
- Hemoglobin ≥ 9 g/dL
- PT or INR < 1.5 x ULN unless on anti-coagulant therapy
- PTT < 1.5 x ULN unless on anti-coagulant therapy
Hepatic:
- Bilirubin ≤ 1.5 x ULN
- ALT ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
- AST ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
Renal:
- Creatinine < 1.5 X upper limit of normal (ULN)
Cardiovascular:
- No significant history of cardiac disease: Congestive heart failure > class II NYHA.
- Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within 90 days prior to registration for initial therapy) or myocardial infarction within 6 months prior to registration for initial therapy.
Respiratory:
- FEV1 ≥ 1 liter by spirometry within 60 days prior to registration for initial therapy.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
Illinois
-
Galesburg, Illinois, 미국, 61401
- Medical & Surgical Specialists, LLC
-
-
Indiana
-
Fort Wayne, Indiana, 미국, 46815
- Fort Wayne Oncology & Hematology, Inc
-
Goshen, Indiana, 미국, 46527
- Center for Cancer Care at Goshen Health System
-
Indianapolis, Indiana, 미국, 46202
- Indiana University Cancer Center
-
Lafayette, Indiana, 미국, 47905
- Horizon Oncology Center
-
Muncie, Indiana, 미국, 47303
- Medical Consultants, P.C.
-
South Bend, Indiana, 미국, 46601
- Northern Indiana Cancer Research Consortium
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45247
- Oncology Partners Network
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histological or cytological proof of non-small cell lung cancer (NSCLC).
- Measurable or non-measurable disease per RECIST.
- Unresectable Stage IIIA or IIIB disease as evaluated by imaging.
- Must be age ≥ 18 years at the time of consent.
- Written informed consent and HIPAA authorization for release of personal health information.
- Females of childbearing potential and males must be willing to use an effective method of contraception.
- Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for initial therapy.
Exclusion Criteria:
- No prior chemotherapy or radiotherapy for lung cancer.
- No positive supraclavicular or scalene lymph nodes extending up into the cervical region.
- No superior sulcus (pancoast tumors).
- No malignant pleural effusions. The only exception is a patient with a pleural effusion visible only on CT scan (and not visible on CXR) OR deemed too small to tap.
- No clinically significant or malignant pericardial effusions.
- No CNS metastases.
- No unintended weight loss (> 5% body weight) in the preceding 90 days prior to registration for initial therapy.
- No treatment with any investigational agent within 30 days prior to being registered for initial therapy.
- No prior therapy with a Ras pathway inhibitor or anti-angiogenic agent.
- No other active cancers.
- Females must not be breastfeeding.
- No active clinically serious infections as judged by the treating investigator (> CTC v3, Grade 2) including known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- No major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration for initial therapy.
- No anticipation of need for major surgical procedure during the course of the study.
- No minor surgical procedures such as fine needle aspirations or cone biopsies within 7 days prior to registration for initial therapy.
- No history of allergic reactions to drugs utilizing the vehicle polysorbate 80 + polyethylene glycol (etoposide).
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to registration for initial therapy.
- No use inhibitors or inducers of the cytochrome p450 system CYP3A4 enzyme or other medications such as aprepitant, ketoconazole, itraconazole, quinidine, digoxin, cyclosporine, ritonavir, grapefruit products, St. John's Wort, rifampin (rifampicin), carbamazepine, phenytoin, dexamethasone, and phenobarbital.
- No evidence or history of bleeding diathesis or coagulopathy.
- No serious non-healing wound, ulcer, or bone fracture.
- No known or suspected allergy to sorafenib.
- No uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management.
- No thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within 6 months prior to registration for initial therapy.
- No pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks prior to registration for initial therapy.
- No hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to registration for initial therapy.
- No condition that impairs patient's ability to swallow whole pills or any malabsorption problem.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Investigational Treatment
Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
|
Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Time to Disease Progression (TTP)
기간: 18 months
|
18 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
전반적인 생존
기간: 18개월
|
18개월
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 의자: Nasser Hanna, M.D., Hoosier Oncology Group, LLC
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- HOG LUN06-107
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .